9 recruiting. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 9 |
| Phase 1 | 1 | Recruiting 1 |
Follow Thymoma: new trials by email Literature Review of Thymoma trials Research Report on Thymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma Sacituzumab tirumotecan - Thymic Carcinoma | Phase 2 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 30 | 2026-03-13 | 2026-08-12 |
| Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma Cyclophosphamide, Fludarabine, EB-CAR30-NK - B2 Thymoma, Thymic Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-05-20 |
| Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma Experimental: tislelizumab+anlotinib - Thymic Carcinoma, Thymoma | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 20 | 2025-03-31 | 2025-12-01 |
| Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma Radiotherapy, Concurrent chemotherapy, Methylprednisolone - Thymoma | Phase 2 | Recruiting | Sun Yat-sen University | 45 | 2024-11-20 | 2024-12-12 |
| A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors Sacituzumab govitecan-hziy - Thymoma, Thymic Carcinoma | Phase 2 | Recruiting | Georgetown University | 18 | 2024-04-25 | 2026-09-11 |
| Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors carbon ion radiotherapy - Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy | Phase 2 | Recruiting | Jian Chen | 48 | 2024-01-26 | 2025-06-13 |
| Neoadjuvant Treatment For Locally Advanced Thymic Cancer Envolizumab combined with radiotherapy - Thymic Carcinoma | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 25 | 2023-11-04 | 2026-05-08 |
| First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) MK-3475, Lenvatinib, Carboplatin - Untreated Advanced or Recurrent Thymic Carcinomas | Phase 2 | Recruiting | National Cancer Center, Japan | 35 | 2023-09-04 | 2023-10-23 |
| PT-112 in Subjects With Thymoma and Thymic Carcinoma PT-112 - Thymic Epithelial Tumor, Recurrent Thymoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 53 | 2022-04-06 | 2026-10-16 |
Thymic epithelial tumor (2) · Peripheral Nervous System Diseases (1) · Thymus Neoplasms (1)
Hemic and Lymphatic Diseases (9) · Lymphatic Diseases (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Complex and Mixed (9) · Thoracic Neoplasms (9) · Thymus Neoplasms (8) · Nervous System Diseases (1) · Neuromuscular Diseases (1)
Radiotherapy (2) · AP 1903 reagent (1) · Carboplatin (1) · Cyclophosphamide (1) · Heavy Ion Radiotherapy (1) · Methylprednisolone (1) · Paclitaxel (1) · envafolimab (1) · fludarabine (1) · lenvatinib (1) · pembrolizumab (1)
Beijing Biotech (1) · Georgetown University (1) · Jian Chen (1) · National Cancer Center, Japan (1) · National Cancer Institute (NCI) (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (1) · Sun Yat-sen University (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (6) · United States (2) · Japan (1)
Arun Rajan, M.D. (1) · Chul Kim, MD (1) · Deping Zhao, MD,PhD (1) · Jian Chen, M.D. (1) · Yusuke Okuma, MD (1)
PMID 11282421, PMID 12778165, PMID 17410014, PMID 18596824, PMID 20930041, PMID 21502559, PMID 21847048, PMID 21847058, PMID 21953501, PMID 23860537, PMID 24974848, PMID 25275083, PMID 25396314, PMID 25402569, PMID 25403584, PMID 25799277, PMID 26291007, PMID 26314779, PMID 27565906, PMID 27876674, PMID 29395863, PMID 29438696, PMID 29906252, PMID 30207917, PMID 30991261, PMID 31772071, PMID 32502444, PMID 33248322, PMID 38413246